A detailed history of Cynosure Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Cynosure Management, LLC holds 3,989 shares of KRYS stock, worth $759,505. This represents 0.11% of its overall portfolio holdings.

Number of Shares
3,989
Previous 4,324 7.75%
Holding current value
$759,505
Previous $794,000 8.69%
% of portfolio
0.11%
Previous 0.13%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$174.7 - $213.66 $58,524 - $71,576
-335 Reduced 7.75%
3,989 $725,000
Q2 2024

Aug 13, 2024

BUY
$153.12 - $183.64 $85,287 - $102,287
557 Added 14.79%
4,324 $794,000
Q1 2024

May 10, 2024

BUY
$108.01 - $179.35 $406,873 - $675,611
3,767 New
3,767 $670,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Cynosure Management, LLC Portfolio

Follow Cynosure Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cynosure Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cynosure Management, LLC with notifications on news.